Salvinorin A - the active ingredient of the hallucinogenic sage Salvia divinorum - along with Salvia divinorum represent emerging drugs of abuse in the US and elsewhere. Salvinorin A and extracts of Salvia divinorum induce an intense and short-lived hallucinatory experience in humans unlike that of the classical hallucinogens LSD, psilocybin and mescaline. In 2002, my lab discovered that salvinorin A potently and specifically targets ?-opioid receptors (KOR) (Roth et al., PNAS 2002);these findings have been widely replicated. Despite intensive interest in the actions of salvinorin A, we still do not fully understand the molecular and atomic mechanisms responsible for its exquisite potency and selectivity at KOR. The goal of these studies is to discover how salvinorin A binds to and activates KOR. To accomplish these goals we will conduct two specific aims: (1) elucidate the structural features of ?-opioid receptors essential for salvinorin A's actions using high-throughput molecular biology and (2) elucidate the structural features of ?-opioid receptors responsible for salvinorin A's actions via direct biochemical approaches. These studies will clarify how this drug of abuse exerts its actions at the atomic level. These studies are significant as follows: Conceptual: Salvinorin A is an emerging drug of abuse which has profound effects on human perception. Salvinorin A exerts these actions via potent and selective activation of ?-opioid receptors. Understanding how salvinorin A achieves its remarkable selectivity and potency for KORs is an essential first step toward elucidating the mechanism of action of salvinorin A. Technical: We will utilize novel and extraordinarily robust yeast-based technologies we have invented (Armbruster et al., 2007a) to identify the molecular and atomic mechanisms by which salvinorin A binds to and activates KORs. We will also employ newly synthesized pM-affinity and irreversible salvinorin A analogues to identify residues on KOR responsible for binding. To our knowledge, these will be the first studies in the opioid receptor field to biochemically identify residues in the binding pocket.
Salvia divinorum and its active ingredient salvinorin A represent emerging drugs of abuse in the US. These studies could lead to novel treatments for drug abuse.
|Polepally, Prabhakar R; Huben, Krzysztof; Vardy, Eyal et al. (2014) Michael acceptor approach to the design of new salvinorin A-based high affinity ligands for the kappa-opioid receptor. Eur J Med Chem 85:818-29|
|Katritch, Vsevolod; Fenalti, Gustavo; Abola, Enrique E et al. (2014) Allosteric sodium in class A GPCR signaling. Trends Biochem Sci 39:233-44|
|Giguere, Patrick M; Kroeze, Wesley K; Roth, Bryan L (2014) Tuning up the right signal: chemical and genetic approaches to study GPCR functions. Curr Opin Cell Biol 27:51-5|
|White, Kate L; Scopton, Alex P; Rives, Marie-Laure et al. (2014) Identification of novel functionally selective *-opioid receptor scaffolds. Mol Pharmacol 85:83-90|
|Lee, Hyeong-Min; Giguere, Patrick M; Roth, Bryan L (2014) DREADDs: novel tools for drug discovery and development. Drug Discov Today 19:469-73|
|Fenalti, Gustavo; Giguere, Patrick M; Katritch, Vsevolod et al. (2014) Molecular control of ?-opioid receptor signalling. Nature 506:191-6|
|Vardy, Eyal; Mosier, Philip D; Frankowski, Kevin J et al. (2013) Chemotype-selective modes of action of ?-opioid receptor agonists. J Biol Chem 288:34470-83|
|Riss, Patrick J; Hong, Young T; Marton, Janos et al. (2013) Synthesis and evaluation of 18F-FE-PEO in rodents: an 18F-labeled full agonist for opioid receptor imaging. J Nucl Med 54:299-305|
|Roth, Bryan L (2013) Impossible or merely difficult? Two grand challenges from a biologist's perspective. ACS Med Chem Lett 4:316-318|
|Lin, Henry; Sassano, Maria F; Roth, Bryan L et al. (2013) A pharmacological organization of G protein-coupled receptors. Nat Methods 10:140-6|
Showing the most recent 10 out of 39 publications